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Tissue fibrosis, defined as an excessive accumulation of extracellular matrix 
components leading to the destruction of organ architecture and impaired function, 
affects virtually every tissue and organ in the body, including the arteries. Vascular 
fibrosis of small and large arteries contributes to arterial remodeling, important in the 
development and complications of hypertension (1). Fibrogenesis is an active process 
that involves accumulation of structural proteins (collagen and fibronectin) and 
adhesion proteins (laminin and fibronectin), expression of adhesion molecules and 
integrins, and remodeling of the extracellular matrix (2,3). Healthy arteries are 
surrounded by perivascular adventitial tissue comprising collagens I and III in the 
intima, media and adventitia, with collagen types I, III, IV and V in the endothelial and 
vascular smooth muscle cell basement membranes (4). These fibrillar proteins 
maintain vascular integrity and normal vascular tone and function. In hypertension, 
accumulation of collagen and fibronectin and extracellular matrix reorganization lead 
to increased stiffness of the vessel wall (5,6). Initially these processes are adaptive and 
reversible and may compe sate for higher blood pressures, but with time and 
progressive increases in blood pressure, this becomes maladaptive and decompensated, 
leading to arterial stiffness that contributes to hypertension-associated target organ 
damage. These events have been demonstrated in many experimental models of 
hypertension and in hypertensive patients and have been attributed to activation of 
ERK1/2, p38MAPK, TGFb, SMAD pathways, oxidative stress and dysregulation of 
matrix metalloproteinases (MMPs) (7). Decreased activation of MMPs and increased 
activity of TIMPs leads to reduced collagen turnover and consequent accumulation, 
with thickening and remodeling of the vascular wall. 
Vascular fibrosis is a dynamic and active phenomenon, where a pro-
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inflammatory, oxidative milieu, triggered by pro-hypertensive stimuli, lays the 
foundation for fibrosis and activation of extracellular matrix-producing cells. Until 
recently the process seemed fairly simple where adventitial fibroblasts and 
myofibroblasts were considered the major collagen-producing cells in the vascular wall 
(8,9). What is becoming increasingly evident is that a whole array of cells have 
potential to produce ECM proteins. In fact, myofibroblasts are differentiated from 
various precursors including adventitial fibroblasts, pericytes, phenotypic transition of 
endothelial cells, phenotypic modulation of vascular smooth muscle cells and 
recruitment of circulating multipotent monocytes and fibrocytes (10). However, the 
scenario continues to become more complex, as demonstrated by Wu et al (11) who 
demonstrate that three previously unidentified cell types, including Sca-1+ progenitor 
cells, bone marrow-derived infiltrating fibrobrocytes and cells of endothelial origin 
(endothelial-to-mesenchymal transition) are major vascular-fibrosing cells in 
hypertension. These findings undersco e the complexity of fibrogenesis and highlight 
the heterogeneous cell pool that contributes to ECM production, vascular fibrosis and 
arterial stiffening.  
Moreover, and rather intriguingly, it seems that pre-differentiated resident 
fibroblasts represent only a minor fraction of ECM-producing cells in hypertension, 
with Sca-1+ cells and bone marrow-derived cells accounting for over 50% of aortic 
collagen-producing cells and cells of endothelial origin contributing around 25% (11). 
These findings further indicate that not only are there multiple types of ECM proteins 
(elastin, fibrin, fibronectin) and collagens (I, III, IV) that contribute to fibrosis  (12) but 
that the process is highly regulated and involves transformation, recruitment and 
activation of different types of collagen-producing cells.  
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 Stem cell antigen-1 (Sca-1) is an 18 kDa mouse glycosyl phosphatidylinositol-
anchored cell surface protein of the Ly6 gene family (13). It was originally identified 
as an antigen that was upregulated on activated lymphocytes and is commonly used as 
a marker of hematopoietic stem cells. Beyond the hematopoietic system, Sca-1 is 
expressed in a mixture of stem, progenitor and differentiated cell types, in various 
tissues and organs including the heart and vessels (14). Sca-1+ adventitial cells are 
embryonic hematopoietic cells and have the capacity to differentiate into various 
vascular cell types, including vascular smooth muscle cells (13,14). In the heart, 
resident Sca-1+ cells may play a regenerative role post myocardial infarction and in the 
vascular wall (15), resident Sca-1+ cells have been implicated in remodeling associated 
with arteriosclerosis (16). Resident vascular adventitial macrophage Sca-1+ progenitor 
cells are abundant in atherosclerotic lesions in hyperlipidemic ApoE(-/-) and LDL-R(-
/-) mice (17). Taken together these data suggest that Sca-1+ cells play a role in 
atherogenesis. Extending these findings, Wu et al (11) show that resident vascular Sca-
1+ cells also contribute to vascular fibr sis in Ang II-induced hypertension. Factors 
that trigger such events have not been clearly elucidated, but the fact that Sca-1+ cells 
were found to be a major source of collagen in aortic fibrosis in hypertension indicates 
that highly regulated systems must be involved. While these intriguing findings 
highlight a key role for embryonic Sca-1+ hematopoietic-derived cells in vascular 
fibrosis in a mouse model of hypertension, the clinical relevance remains unclear, 
because Sca-1+ antigen is absent in humans (14).  
Not only were resident Sca-1+ progenitor cells identified to be a significant 
source of collagen in vascular fibrosis (11), but bone marrow-derived circulating 
fibrocytes were found to be especially important and to constitute the majority of cell 
types responsible for ECM production in the aorta in Ang II-induced hypertension. 
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This is not a new finding, since others have demonstrated that bone marrow-derived 
circulating progenitor cells are recruited to sites of vascular injury and to assume 
endothelial, smooth muscle-like and fibroblast-like phenotypes (18). Fibrocytes, which 
express leukocyte antigen CD45, produce ECM components and ECM-modifying 
enzymes, such as MMPs, and can differentiate into myofibroblasts and play a role in 
vascular remodeling and fibrosis in pulmonary hypertension. In Ang II-induced 
hypertension, fibrocytes seem to be especially important in vascular fibrosis, since Wu 
et al found that the majority of collagen I-producing cells of the aorta are CD45+Col I+ 
bone marrow-derived fibrocytes (11). What still needs to be identified are the specific 
factors involved in the recruitment and retention of these cells, although an underlying 
pro-inflammatory environment could be important because chemokines and cytokines 
seem to attract circulating fibrocytes to the vascular wall (11).  
Wu et al (11) described a third novel mechanism contributing to aortic fibrosis 
in Ang II-induced hypertension, involving endothelial-to-mesenchymal transition 
(EMT), a process whereby differentiated endothelial cells undergo a phenotypic 
conversion to matrix-producing fibroblasts and myofibroblasts. EMT is usually 
preceded by and closely associated with inflammation and may be an adaptive 
response to endothelial injury (19). Underlying vascular inflammation in hypertension 
may stimulate signaling pathways such as TGFb/Smad, integrin-linked kinase (ILK) 
and Wnt/b-catenin, which are critically involved in the process of EMT (20). 
Interestingly, many of these signaling molecules are themselves implicated in the 
production of ECM proteins. Hence molecular mechanisms promoting EMT are 
similar to those that drive fibrosis, and as such may be putative targets of antifibrotic 
therapy.  
While a new paradigm in aortic fibrosis in hypertension has been defined (11), 
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there are a number of questions that still need to be answered. Firstly, do similar 
cellular populations participate in vascular fibrosis of small arteries, the vessels that 
contribute to increased resistance and blood pressure elevation? Secondly, do Sca-1+ 
cells, bone marrow-derived fibrocytes and ETM cells in the vascular wall produce 
different types of ECM proteins and collagens? Thirdly, do the cell types have a 
distinct localization in the aorta and are they activated at different time points during 
fibrogenesis? Fourthly, what triggers the activation of these apparently unrelated cells 
to become pro-fibrogenic and finally what are the signaling pathways and mechanisms 
that regulate these different cell types to produce collagen and other ECM in a 
regulated and organized manner in the vascular wall?  
Our previous notion that adventitial resident fibroblasts are the cellular origin 
and backbone of vascular fibrosis clearly needs to change and based on the findings of 
Wu et al (11), we need to now think of fibrosis as a complex multi-cellular 
phenomenon where recruitment, differentiation and transformation of various cell 
types define the ECM in hypertension. Moreover, from a therapeutic viewpoint, this 
new paradigm highlights the potential importance to target multiple cell types and 
different systems in the prevention of vascular fibrosis and aortic stiffening in 
hypertension. 
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Figure legend 
Diagram demonstrating a role for multiple cell types in vascular fibrosis in 
hypertension. Pro-hypertensive factors, such as angiotensin II (Ang II) and 
proinflammatory stimuli, stimulate activation of bone marrow-derived fibrocytes, Sca-
1+ vascular cells, resident fibroblasts and myofibroblasts as well as endothelial-to-
mesenchymal transition (EMT). Inflammation in particular stimulates EMT. Activation 
of these cells is associated with stimulation of pro-fibrotic signaling pathways, leading 
to production of extracellular matrix (ECM) proteins, such as collagens and 
fibronectin. These processes lead to vascular fibrosis and arterial stiffening in 
hypertension. ILK, integrin-linked kinase; MAPK, mitogen-activated protein kinases; 
ROS, reactive oxygen species. The study of Wu et al (11) suggests that the major cell 
types contributing to vascular fibrosis in Ang II-induced hypertension involve bone 
marrow-derived fibrocytes and Sca-1+ cells. 
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